Status:
COMPLETED
Comparative Study of Use of Alpha-Blockers to Treat Symptoms in Prostate Cancer Patients Undergoing Radiation Therapy
Lead Sponsor:
Sir Mortimer B. Davis - Jewish General Hospital
Conditions:
Urinary Problems
Prostate Cancer
Eligibility:
MALE
18+ years
Phase:
PHASE3
Brief Summary
Approximately 50%-95% of prostate cancer patients undergoing radiation therapy (RT) develop symptomatic urinary problems .These symptoms can significantly diminish a patient's quality of life during a...
Detailed Description
The efficacy of Rapaflo treatment will be assessed using the International Prostate Symptom Score (IPSS). The IPSS will be assessed at baseline before RT, 4 weeks into RT, the last day of RT, and mont...
Eligibility Criteria
Inclusion
- Adult male 18 years of age or older
- Patients with confirmed diagnosis of adenocarcinoma of the prostate.
- The primary treatment should be external beam radiation therapy (EBRT) with or without high dose rate (HDR) brachytherapy boost.
- Clinical or radiological diagnosis of T1a - T3b.
- No limitation with respect to Gleason score.
- No limitation with respect to total Prostate-specific Antigen (PSA) value.
- Karnofsky performance score (KPS) of ≥ 70.
Exclusion
- Small cell cancer of the prostate
- T4 disease, invading bladder or rectum.
- Adjuvant or salvage radiation therapy
- Brachy monotherapy
- KPS \< 70
Key Trial Info
Start Date :
June 1 2016
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2023
Estimated Enrollment :
148 Patients enrolled
Trial Details
Trial ID
NCT02220829
Start Date
June 1 2016
End Date
August 1 2023
Last Update
December 9 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Jewish General Hospital, McGill University
Montreal, Quebec, Canada, H3T 1E2